Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.730
+0.600 (14.53%)
At close: May 14, 2026, 4:00 PM EDT
4.480
-0.250 (-5.28%)
Pre-market: May 15, 2026, 5:32 AM EDT

Aquestive Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
59378832513849160
Market Cap Growth
122.06%142.26%135.08%179.90%-69.16%-13.28%
Enterprise Value
526.23699.09291.36147.4760.72185.85
Last Close Price
4.736.463.562.020.903.89
PE Ratio
--8.28-6.98-15.54-0.81-2.10
PS Ratio
11.8017.705.652.741.043.16
PB Ratio
--23.42-5.41-1.30-0.42-1.95
P/TBV Ratio
-15.78-20.52-5.13-1.16-0.37-1.80
P/FCF Ratio
--14.88-9.06-18.77-4.56-4.73
P/OCF Ratio
--15.04-9.10-21.70-5.04-4.86
EV/Sales Ratio
10.4715.695.062.921.273.66
EV/EBITDA Ratio
--9.92-9.69-10.72-1.53-5.86
EV/EBIT Ratio
--9.84-9.47-9.77-1.44-5.36
EV/FCF Ratio
--13.19-8.11-20.00-5.60-5.48
Debt / Equity Ratio
-0.86-0.95-0.62-0.31-0.33-0.65
Debt / EBITDA Ratio
-0.79-0.60-1.26-2.42-1.45-1.78
Debt / FCF Ratio
-0.98-0.80-1.06-4.52-5.30-1.66
Net Debt / Equity Ratio
1.972.340.56-0.09-0.25-0.35
Net Debt / EBITDA Ratio
1.211.121.12-0.69-0.76-0.89
Net Debt / FCF Ratio
1.521.490.93-1.28-2.79-0.84
Asset Turnover
0.330.340.720.880.800.81
Inventory Turnover
2.583.042.793.323.954.61
Quick Ratio
3.702.924.181.770.811.83
Current Ratio
4.103.144.682.241.012.15
Return on Equity (ROE)
203.53%178.61%53.01%6.56%54.22%108.00%
Return on Assets (ROA)
-37.07%-54.27%-38.76%-25.53%-70.66%-55.54%
Return on Invested Capital (ROIC)
-575.65%-787.31%-193.55%-97.42%-292.09%-214.48%
Return on Capital Employed (ROCE)
-50.31%-72.73%-50.58%-53.31%-146.14%-84.78%
Earnings Yield
-11.61%-12.07%-14.33%-6.44%-124.15%-47.56%
FCF Yield
-7.47%-6.72%-11.04%-5.33%-21.92%-21.13%
Buyback Yield / Dilution
-23.33%-23.29%-41.58%-25.69%-27.99%-13.15%
Total Shareholder Return
-23.33%-23.29%-41.58%-25.69%-27.99%-13.15%
Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q